In other words, NK cells possess the ability to activate interleukin-15 (IL-15) to mitigate tumor mutational burden in SCLC models, indicating that targeting NK cells within the SCLC microenvironment may provoke a specific response. This evidence concerns the gene IL15 and neoplasm.